Loading news...
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 19,215 shares of the firm's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the sale, the chief executive officer owned 306,891 shares of the
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Will Lewis, Insmed CEO, joins 'Fast Money' to talk the rare disease pipeline, acquisitions in the pharma space, and more.
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CFO Sara Bonstein sold 1,678 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $175.07, for a total value of $293,767.46. Following the completion of the sale, the chief financial officer directly owned 81,953 shares in the
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CFO Sara Bonstein sold 1,447 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $174.17, for a total transaction of $252,023.99. Following the transaction, the chief financial officer directly owned 80,506 shares in the company, valued at
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 1,053 shares of the business's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total transaction of $183,401.01. Following the completion of the sale, the insider directly owned 57,037 shares of the
Insmed, Inc. (NASDAQ: INSM - Get Free Report) COO Roger Adsett sold 1,429 shares of the firm's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $173.33, for a total transaction of $247,688.57. Following the sale, the chief operating officer directly owned 110,462 shares in the
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 1,396 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $173.33, for a total transaction of $241,968.68. Following the completion of the sale, the insider directly owned 58,799 shares of the
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CFO Sara Bonstein sold 1,517 shares of Insmed stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $173.33, for a total transaction of $262,941.61. Following the completion of the transaction, the chief financial officer directly owned 83,631 shares of the
Insmed Inc (NASDAQ: INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company's growth over the next 18 months.
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately $433.8 Million— —Full-Year 2026 Global ARIKAYCE Revenues Expected to be Between $450 Million and $470 Million— —Topline Data from Phase 3 ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Now Anticipated in March or April of 2026— — Topline Data from Phase 2b CEDAR Study of Brensocatib in Patients with HS Now Anticipated in the Second Quarter of 2026— — Phase 3 PALM-ILD Study of TPIP in PH-ILD Initiated in the Fourth Quarter of 2025; Additional Phase 3 Studies Planned for PAH, PPF, and IPF in 2026— BRIDGEWATER, N.J., Jan. 9, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2026.
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the J.P.
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.